

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.usplo.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR.	ATTORNEY DOCKET NO.	CONFIRMATION NO
10/031,915	01/18/2002	Jennifer Hillman .	PF-0722 USN	1605
27904	7590 03/09/2004		EXAMINER	
INCYTE CORPORATION			CARLSON, KAREN C	
3160 PORTER DRIVE PALO ALTO, CA 94304			ART UNIT	PAPER NUMBER
TALO ALTO,			1653	
			DATE MAILED: 03/09/200	4

Please find below and/or attached an Office communication concerning this application or proceeding.

La Carlo Car	Application No.	Applicant(s)			
	10/031,915	HILLMAN ET AL.			
Office Action Summary	Examiner	Art Unit			
	Karen Cochrane Carlson, Ph.D.	1653			
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the c	correspondence address			
A SHORTENED STATUTORY PERIOD FOR REPL THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a repleter of the period for reply is specified above, the maximum statutory period. Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	136(a). In no event, however, may a reply be tir ply within the statutory minimum of thirty (30) day I will apply and will expire SIX (6) MONTHS from te, cause the application to become ABANDONE	nely filed s will be considered timely. the mailing date of this communication. D (35 U.S.C. § 133).			
Status					
1) Responsive to communication(s) filed on 12 s	January 2004.				
Since this application is in condition for allowated closed in accordance with the practice under	ance except for formal matters, pro				
Disposition of Claims					
4) ⊠ Claim(s) 1-11,13,15-19,22,25,26 and 28-192 4a) Of the above claim(s) is/are withdra 5) □ Claim(s) is/are allowed. 6) ⊠ Claim(s) 1-7,9,11,16,17,59,105,151 and 184- 7) □ Claim(s) is/are objected to. 8) □ Claim(s) are subject to restriction and/or	awn from consideration. 192 is/are rejected.				
Application Papers					
9) The specification is objected to by the Examination The drawing(s) filed on is/are: a) accomposed and applicant may not request that any objection to the Replacement drawing sheet(s) including the correction. The oath or declaration is objected to by the Examination.	cepted or b) objected to by the lead of a cepted or b) objected to by the lead of a cepted of the drawing(s) is objection is required if the drawing(s) is objection is	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).			
Priority under 35 U.S.C. § 119					
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority document 2. Certified copies of the priority document 3. Copies of the certified copies of the priority document application from the International Bureat * See the attached detailed Office action for a list	nts have been received. Its have been received in Applicationity documents have been received au (PCT Rule 17.2(a)).	on No ed in this National Stage			
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948)	4)				
Notice of Draitsperson's Patent Drawing Review (PTO-946) Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08 Paper No(s)/Mail Date		latent Application (PTO-152)			

Art Unit: 1653

Applicant's election with traverse of Invention 76, drawn to the polynucleotides encoding SEQ ID NO: 36, Claims 3-7, 9, 11, 105, 151, and 184-192 in the paper filed January 12, 2004 is acknowledged. The traversal is on the ground(s) that this is a national stage application filed under 371 and that lack of unity must be shown. This is not found persuasive because lack of unity was demonstrated in the Lack of Unity, Form 206, in the parent PCT application. Also, unity of invention only applies to the first invention, that is, to SEQ ID NO: 1, which Applicants did not elect. Applicants have also requested rejoinder of the polypeptide having SEQ ID NO: 36, Claims 1, 2, 16, 17, and 59. No additional search burden is required and these claims have also been examined.

The requirement is still deemed proper and is therefore made FINAL.

The Examiner thanks Applicants for pointing out that many claims had been canceled prior to restriction. The Examiner appreciates that Applicants have elected an invention even though the restriction requirement included these canceled claims. The Examiner apologizes for the confusion; the USPTO has recently begun scanning the files into electronic format and at this time the these electronic forms of older files do not readily show that claims have been canceled.

Claims 12, 14, 20, 21, 23, 24, and 27 have been canceled. Claims 8, 10, 13, 15, 18, 19, 22, 25, 26, 28-58, 60-104, 106-150, and 152-183 have been withdrawn from further consideration by the Examiner because these claims are drawn to non-elected inventions. Claims 1-7, 9, 11, 16, 17, 59, 105, 151, and 184-192 under currently under examination.

Priority is set to November 10, 1999, in which SEQ ID NO: 14 of provisional application 60/164,647 is instant Claim 36. Other provisional applications should be deleted from the priority listing.

Art Unit: 1653

The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. See the hyperlink at page 19, para. 1, for example.

Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

35 U.S.C. 101 reads as follows:

Whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title.

Claims 1-7, 9, 11, 16, 17, 59, 105, 151, and 184-192 are rejected under 35 U.S.C. 101 the claimed invention lacks patentable utility. It does not appear that the information provided in the specification regarding the polynucleotides having SEQ ID NO: 90 and encoding the polypeptide having SEQ ID NO: 36 is accurate or complete. Thus, the claimed products are not useful.

At page 8 of the specification, the encoding polypeptide having SEQ ID NO: 36 is said to be one of 54 cell cycle and proliferation proteins (CCYPR), specifically referred to as CCYPR-36. As a whole, these CCYPRs and polynucleotides encoding them are stated to be useful for the diagnosis, prevention, and treatment of immune, developmental, and cell signaling disorders, and cell proliferation disorders including cancers (page 8, para. 1). No specific activity is exemplified or attributed to any of the 54 CCYPRs, and no direction on how the any of the polynucleotides can be used in such a manner is provided.

The encoded polypeptide having SEQ ID NO: 36 is stated in Table 2 at page 87 to have homology to malignant brain tumor protein, which is cited to Koga et al. (1999; Oncogene 18:3799-3809). Koga et al. describes the human homology of *Drosophila* lethal (3) malignant brain tumor (I3mbt) protein, a tumor suppressor protein. In contrast to the 445 amino acid

Art Unit: 1653

sequence of SEQ ID NO: 36, Koga et al. describes h-I(3)mbt as having 772 amino acids. Thus, the instant CCYPR-36 is a much shorter amino acid sequence that the h-I(3)mbt protein which the specification looks to for utility and enablement. The polynucleotide sequence encoding h-I(3)mbt is 3394 nucleotides and maps to chromosome 20, and is a single open reading frame encoding the 772 amino acid sequence. See Koga et al. at page 3800, Fig1A; page 3801, Fig 1C and right col. An alternative splice isoform (page 3802) was also identified as having 738 amino acids.

At page 28 of the specification, the polynucleotides having SEQ ID NO: 90 (encoding SEQ ID NO: 36) is said to map to chromosomes 2, 3, and 6. It is not possible for a specific nucleotide sequence comprising 2555 nucleotides to be found on three different chromosomes. Further, this is incongruent with Koga et al. who state that the polynucleotides encoding h-I(3)mbt protein maps to chromosome 20.

Therefore, given that the polynucleotides SEQ ID NO: 90 is taught in the specification to map to chromosomes 2, 3, and 6, rather than chromosome 20 as taught in the cited reference Koga et al., and the encoding polypeptide having SEQ ID NO: 36 is over 220 amino acids shorter than the h-I(3)mbt taught in Koga et al., the specification does not provide a basis for stating that the polypeptide and encoding polynucleotides have homology, and therefore implied potential like activity, to h-I(3)mbt as taught in Koga et al.

Perusal of additional art also provides evidence that Applicants are not in any meaningful possession of a malignant brain tumor protein, or its encoding polynucleotides. Wismar et al. (2001; FEBS Letters 507:199-121) teach human lethal (3) malignant brain tumor-like 2 protein (LML2), which is a 705 amino acid polypeptide that encompasses all of SEQ ID NO: 36 from amino acids 211-705 of LML2. Thus, Wismar et al.'s LML2 comprises a 210 amino acid N-terminus when compared to SEQ ID NO: 36, and this additional length is similar to that described

Art Unit: 1653

in Koga et al. The polynucldotide encoding LML2 encompasses SEQ ID NO: 90, and maps to chromosome 22.

In total, the polynucleotides encoding SEQ ID NO: 36, or the polypeptide having SEQ ID NO: 36 lack utility because Applicants are not in possession of either full-length product, and the specification provides information that is incongruent and/or lacking when the products are compared to the art of record. One skilled in the art could not identify these products as they are set forth in the specification if they were to come upon them in the lab or reading art references, for example. These products do not exist as described.

Claims 1-7, 9, 11, 16, 17, 59, 105, 151, and 184-192 also rejected under 35 U.S.C. 112, first paragraph. Specifically, since the claimed invention is not supported by either a the asserted utility or a well established utility for the reasons set forth above, one skilled in the art clearly would not know how to use the claimed invention.

The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

Claims 1, 3, 6, 7, 9, 11, 16, 17, and 184-192 are rejected under 35 U.S.C. 112, first paragraph, as containing subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention. The Claims refer to percent identity, biologically active fragments, and immunologically active fragments, polynucleotides that hybridize to claimed polynucleotides, and so forth. The specification does not describe any

Art Unit: 1653

of these variants, or any variant having any activity. Therefore, the specification lacks written description.

The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

Claims 1-7, 9, 11, and 184-192 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

The activity of a biologically active fragment is not set form in Claim 1. It is not clear what an immunogenically active fragment of SEQ ID NO: 36 is, that is, for example, what kind of antibody does an immunogenically active fragment generate?

Claim 184 depends from canceled Claim 12, and has been taken to depend from Claim 1 to advance the prosecution. Claims 186 and 190 refer to hybridization but no conditions are set forth, rendering the claims indefinite.

The Claims still comprise non-elected subject matter and therefore it is indefinite what the elected subject matter is.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Karen Cochrane Carlson, Ph.D. whose telephone number is 571-272-0946.

The examiner can normally be reached on 7:00 AM - 4:00 PM, off alternate Fridays.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Dr. Christopher Low can be reached on 571-272-0951. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Art Unit: 1653

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

KAREN COCHRANE CARLSON, PH.D PRIMARY EXAMINER

Kan Cochane Carbon Drs